
Overview
Roche Polska focuses on discovering new medicines, diagnostics and digital healthcare solutions. The company develops medicines, therapies and diagnostic solutions, conducts clinical research and has used energy exclusively from renewable sources in its buildings since 2024.
Financials
Revenue history (in m)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 366 days for 2023). All were audited by a statutory auditor.
- 2025not filed
- 202418/07/2025
- 202316/07/2025
- 202225/07/2023
- 202103/10/2022
- 202023/12/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
News

Press conference on hemophilia A, 31.08.2026

Information on the reimbursement status of Hemlibra (emicizumab)

Information on the reimbursement status of Hemlibra (emicizumab)

Information on the reimbursement status of Hemlibra (emicizumab)

Important information on the end of distribution of Gavreto (pralsetinib) by Roche Polska

Information on the reimbursement status of Hemlibra (emicizumab) – update of 2 April 2026
Industry
Public procurement
1193 tenders recorded as contractor: 192 national ($12,905,823) and 1001 EU ($1,434,003,443).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Nov 17, 2026 | Supply of various medicines, including programme medicines | –– | Szpital Wojewódzki Im. Jana Pawła II w Bełchatowie | |
| Nov 16, 2026 | DFP.271.124.2026.JB Supply of medicinal products | $1.9M$1,877,796 | Szpital Uniwersytecki w Krakowie | |
| Nov 12, 2026 | Supply of medicines. | $140.4K$140,365 | Centrum Onkologii Ziemi Lubelskiej Im. Św. Jana z Dukli |
The company is the contractor in 257 public sector contracts, worth USD 130.48m in total. They were signed with 99 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Nov 13, 2026 | COLUMVI 10MG/10ML X 1 FIOL. - 3 OP. | $8,033 | Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kielcach | |
| Nov 12, 2026 | Medicines for drug programmes, chemotherapy medicines | $8,439 | Wojewódzki Szpital Zespolony Im. Dr. Romana Ostrzyckiego w Koninie | |
| Nov 10, 2026 | Medicines. | $10,576,545 | Uniwersyteckie Centrum Kliniczne |
Job offers
The company has its own careers page: careers.roche.com.
Authorized Representatives
Manner of representation
Two members of the management board jointly, or one member of the management board together with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Roche Finanz Ag | 25,000 | $6,753,106.43 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Roche Finanz AG (Switzerland) group, which is its direct owner.
Bank accounts
Registered as a VAT taxpayer on 2003-12-31.
17 1880 0009 0000 0011 0283 5000
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 30, 2014 | Return of additional payments |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Komtur Polska sp. z o.o. | $424,362,396.43 | komtur.pl | ||
| Sanofi sp. z o.o. | $384,123,246.36 | sanofi.com | ||
| MSD Polska Dystrybucja sp. z o.o. | $341,786,056.16 | msd.pl | ||
| Polpharma Biologics S.A. | $311,661,837.06 | polpharmabiologics.com | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Pfizer Polska sp. z o.o. | $110,632,345.55 | pfizer.pl | ||
| Ipsen Poland sp. z o.o. | $94,814,847.87 | ipsen.com | ||
| Selvita S.A. | $91,692,114.52 | selvita.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-01-16 | Address change (Domaniewska 39b, 02-672, Warszawa → Ul. Domaniewska 28, 02-672, Warszawa) | |
| 2009-02-16 | Share capital increase (2,000,000.00 PLN → 25,000,000.00 PLN) | |
| 2006-03-07 | Address change (Al. Jerozolimskie 146b, 02-305, Warszawa → Domaniewska 39b, 02-672, Warszawa) | |
| 2002-06-14 | Entered in the register |
FAQ
Last updated: 2026-10-07